Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
NCT ID: NCT06609330
Last Updated: 2025-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2025-03-17
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Will participants be satisfied with the treatment, and is the treatment feasible to do in a military outpatient setting
* Will the treatment help with anger and aggression issues.
Researchers will compare differences in groups that have different wait times (2-, 3-, or 4-weeks).
Participants will complete surveys before, during and after the treatment. The treatment will be 14 modules given twice a week. About 1 month after treatment ends, surveys will be taken again.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Cognitive Behavioral Therapy for Military Populations
NCT02038075
Digital Therapeutic for Depression After Head Injury in Current and Former US Military Personnel
NCT05147506
Parent Management Training to Treat Irritability
NCT06020261
A Study to Assess the Effectiveness of Behavioural Activation Group Therapy in Individuals With Depression
NCT02297282
Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs
NCT02466126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* During the wait time:
* Complete a 5-10 minute assessment twice per week (Monday/Thursday or Tuesday/Friday) to assess level of anger, aggression, and interactions with others since last assessment.
* The assigned therapist will call participants once a week for a 10-minute, check-in.
* At the end of participants' assigned wait time, they will complete an assessment of level of anger, aggression, interactions with others, mental, and physical health.
* During treatment:
* Begin treatment within 1 week of last wait time assessment.
* Participate in 7-24 (average 14) one-hour bi-weekly (Monday/Thursday or Tuesday/Friday) CART sessions.
* Prior to each session, participants will complete the same 5-10 minute assessment to assess level of anger, aggression, and interactions with others since last assessment.
* At the final treatment session, participants will be scheduled to complete a 1-month follow-up assessment.
* For follow-up:
* Complete a 1-month follow up assessment between 4-8 weeks after the final treatment session.
* Participants will be sent a link to complete the follow-up assessment.
* Complete the same questionnaires completed at pre-treatment plus an exit interview and a brief satisfaction survey.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2-week wait time group
This group is randomized to a 2-week wait time prior to treatment with CART
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
3-week wait time group
This group is randomized to a 3-week wait time prior to treatment with CART
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
4-week wait time group
This group is randomized to a 4-week wait time prior to treatment with CART
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART), a novel intervention for reducing chronic anger and aggression and improving interpersonal relationships, in military personnel who have experienced military-related betrayal delivered in 14 treatment modules twice a week.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Endorses a history of military-related betrayal (on the Modified Moral Injury Questionnaire)
* Endorses problematic anger in the past month (as evidenced by a score of 12 or above on the Dimensions of Anger Reactions; DAR-5)
* Engaged in at least 1 self-reported act of aggression in the past 1 month (on the Overt Aggression Scale-Modified; OAS-M)
Exclusion Criteria
* Acute suicidality requiring immediate intervention, such as hospitalization as assessed by the Depressive Symptoms Index-Suicidality Subscale (DSI-SS) combined with follow up clinical interview for elevated scores.
* Is currently homicidal with plans and intent to hurt a specific person and requiring immediate intervention as measured by self-report and follow-up with clinician if screened positive.
* Moderate to severe brain injury as measured by inability to comprehend the informed consent document or baseline assessments.
* Has severe alcohol consumption patterns as evidenced by a score of 19 or above on the Alcohol Use Disorders Identification Test (AUDIT).
* Experiencing active psychosis or mania as measured by the Prodromal Questionnaire-Brief Version and the Mood Disorders Questionnaire.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United States Department of Defense
FED
The University of Texas Health Science Center at San Antonio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vanessa Jacoby
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vanessa Jacoby, PhD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Alan Peterson, PhD
Role: PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Carl R. Darnall Army Medical Center (CRDAMC) at Fort Cavazos
Fort Cavazos, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W81XWH-22-2-0085
Identifier Type: OTHER
Identifier Source: secondary_id
20230329HU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.